Serveur d'exploration sur l'Indium

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Le cluster Somatostatin (diagnostic use) - Receptors, Somatostatin (analysis)

Terms

35Somatostatin (diagnostic use)
21Receptors, Somatostatin (analysis)
29Radiopharmaceuticals (diagnostic use)
21Prospective Studies
14Receptors, Somatostatin (metabolism)
21Iodine Radioisotopes (diagnostic use)
8Iodobenzenes (diagnostic use)
83-Iodobenzylguanidine

Associations

Freq.WeightAssociation
1313Receptors, Somatostatin (analysis) - Somatostatin (diagnostic use)
1111Radiopharmaceuticals (diagnostic use) - Somatostatin (diagnostic use)
1010Prospective Studies - Somatostatin (diagnostic use)
99Receptors, Somatostatin (metabolism) - Somatostatin (diagnostic use)
88Prospective Studies - Receptors, Somatostatin (analysis)
88Iodine Radioisotopes (diagnostic use) - Somatostatin (diagnostic use)
88Iodine Radioisotopes (diagnostic use) - Iodobenzenes (diagnostic use)
883-Iodobenzylguanidine - Iodobenzenes (diagnostic use)
883-Iodobenzylguanidine - Iodine Radioisotopes (diagnostic use)
77Radiopharmaceuticals (diagnostic use) - Receptors, Somatostatin (metabolism)
77Radiopharmaceuticals (diagnostic use) - Receptors, Somatostatin (analysis)
66Prospective Studies - Radiopharmaceuticals (diagnostic use)
55Iodobenzenes (diagnostic use) - Somatostatin (diagnostic use)
55Iodine Radioisotopes (diagnostic use) - Radiopharmaceuticals (diagnostic use)
553-Iodobenzylguanidine - Somatostatin (diagnostic use)
44Prospective Studies - Receptors, Somatostatin (metabolism)
44Iodine Radioisotopes (diagnostic use) - Prospective Studies
33Iodine Radioisotopes (diagnostic use) - Receptors, Somatostatin (metabolism)

Documents par ordre de pertinence
000175 (1998) Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake.
000227 (1994) Scintiscans and carcinoid tumors.
000058 (2009) Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French study.
000125 (2004) Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.
000154 (2000) Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography.
000162 (1999) Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy.
000170 (1999) Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
000172 (1999) Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.
000182 (1997) [Peroperative detection probes. Evaluation and perspectives in endocrinology].
000186 (1997) Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. The Group of Thyroid Tumoral Pathology of Champagne-Ardenne.
000202 (1996) Indium-111-pentetreotide scintigraphy in children with neuroblast-derived tumors.
000205 (1996) Could somatostatin scintigraphy be superior to MIBG scan in the staging of stage IVs neuroblastoma (Pepper's syndrome)?
000206 (1996) Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours.
000223 (1994) Strong uptake of 111In-pentetreotide by an MIBG-negative, xenografted neuroblastoma.
000060 (2009) Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
000106 (2006) Bone metastases from head and neck paragangliomas: uncommon MR findings in an uncommon condition--report of three cases.
000140 (2002) Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.
000142 (2001) Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis.
000168 (1999) Factor analysis of dynamic series (FADS) in somatostatin receptor imaging.
000193 (1997) Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
000207 (1996) Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
000211 (1995) Somatostatin receptor imaging: a preliminary experience in forty-nine patients.
000221 (1995) Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.
000046 (2010) [Somatostatin receptor-based imaging and therapy of digestive endocrine tumors].
000075 (2008) Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy.
000076 (2008) Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.
000085 (2007) Paraneoplastic ACTH secretion: bronchial carcinoid overlooked by planar indium-111 pentetreotide scintigraphy and accurately localized by SPECT/CT acquisition.
000110 (2005) Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.
000114 (2005) Intraoperative and postoperative gamma detection of somatostatin receptors in bone-invasive en plaque meningiomas.
000130 (2003) Octreotide imaging plus bone scintigrams to optimally localize gastroenteropancreatic neuroendocrine tumors.
000135 (2002) [Scintigraphy by l'Octreoscan in the management of head and neck paragangliomas].
000136 (2002) Parathyroid adenoma visualization on octreotide scintigraphy.
000158 (2000) 111In-pentetreotide scintigraphy in patients with Langerhans' cell histiocytosis.
000163 (1999) Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
000180 (1998) In vivo inaccessibility of somatostatin receptors to 111In-pentreotide in primary renal cell carcinoma.
000191 (1997) False-positive somatostatin receptor scintigraphy due to an accessory spleen.
000200 (1996) Left ventricular myocardial uptake of a labeled somatostatin analog in carcinoid syndrome.
000213 (1995) Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
000217 (1995) Indium-111 pentetreotide scintigraphy in malignant lymphomas.
000224 (1994) Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison.
000225 (1994) Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index.
000007 (2013) Sustained therapeutic perfusion outside transplanted sites in chronic myocardial infarction after stem cell transplantation.
000081 (2008) Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model.
000087 (2007) In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer.
000093 (2006) [Imaging strategy for staging and follow-up of endocrine tumors].
000102 (2006) Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis.
000107 (2006) (99m)Tc-annexin V and (111)In-antimyosin antibody uptake in experimental myocardial infarction in rats.
000108 (2005) Validation of the Monte Carlo simulator GATE for indium-111 imaging.
000117 (2005) Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects.
000121 (2004) The usefulness of 99mTc sulfur colloid bone marrow scintigraphy combined with 111In leucocyte scintigraphy in prosthetic joint infection.
000134 (2003) Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck.
000138 (2002) Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives.
000144 (2001) Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms.
000147 (2001) Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases.
000149 (2001) Gastric emptying is accelerated in obese type 2 diabetic patients without autonomic neuropathy.
000161 (1999) Subarachnoid-pleural fistula complicating thoracoscopy: value of In-111 DTPA myeloscintigraphy.
000165 (1999) In-111 pentetreotide scintigraphy to monitor nonsecreting neuroendocrine tumors.
000169 (1999) Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy.
000173 (1999) Cell irradiation caused by diagnostic nuclear medicine procedures: dose heterogeneity and biological consequences.
000174 (1999) 111Indium antimyosin antibody imaging of primary myocardial involvement in systemic diseases.
000189 (1997) Internalization of indium-labeled LDL through a lipid chelating anchor in human pancreatic-cancer cells as a potential radiopharmaceutical for tumor localization.
000192 (1997) Effects of preoperative intentional hemodilution on the extravasation rate of albumin and fluid.
000194 (1996) [Detection of endocrine tumors of the digestive tract. Value and limitations of scintigraphy of somatostatin receptors].
000199 (1996) Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan.
000214 (1995) Per operative localization of a carcinoid tumour of the breast using indium-111 pentetreotide and a nuclear surgical probe.
000216 (1995) Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells.
000218 (1995) Fate of mouse macrophages radiolabelled with PKH-95 and injected intravenously.
000226 (1994) Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor.
000266 (1991) Reproducibility of image interpretation in immunoscintigraphy performed with indium-111- and iodine-131-labeled OC125 F(ab')2 antibody injected into the same patients.
000276 (1990) Scintigraphic assessment of indium-111-labeled granulocyte splenic pooling: a new approach to inflammatory bowel disease activity.
000279 (1990) Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab')2 fragments.
000281 (1990) In vitro binding to granulocytes of two anti-NCA 95 monoclonal antibodies: Mab1 (ORIS) and Mabgc (Mallinckrodt).
000282 (1990) Imaging of inflammatory bowel disease (IBD) and scintigraphic assessment of resected colon: comparison of 111 In-oxine and 99mTC HMPAO leucocyte labelling.
000286 (1989) Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma.
000287 (1989) In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate.
000291 (1989) Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice.
000304 (1987) A new approach to image subtraction in immunoscintigraphy: preliminary results.

Wicri

This area was generated with Dilib version V0.5.76.
Data generation: Tue May 20 07:24:43 2014. Site generation: Thu Mar 7 11:12:53 2024